FDA lifts hold on fitusiran trials

Sanofi (Euronext:SAN; NYSE:SNY) and partner Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said FDA lifted clinical holds on studies of hemophilia candidate fitusiran (ALN-AT3, SAR439774), including the Phase III ATLAS

Read the full 275 word article

User Sign In